NAGLU (Alpha-N-Acetylglucosaminidase) is a lysosomal enzyme essential for the degradation of heparan sulfate glycosaminoglycans. Mutations in NAGLU cause mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B, a devastating neurodegenerative lysosomal storage disorder. This page provides detailed information about NAGLU's structure, function, and role in disease processes.
NAGLU encodes alpha-N-acetylglucosaminidase, a lysosomal enzyme that catalyzes the N-acetylglucosaminide hydrolysis in heparan sulfate glycosaminoglycans. It is the third enzyme in the stepwise degradation of heparan sulfate, working in concert with N-sulfoglucosamine sulfohydrolase (SGSH) and heparan N-sulfatase (HGSNAT) to completely break down HS chains [1].
Mutations in NAGLU cause mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B, a neurodegenerative lysosomal storage disorder. The enzyme deficiency leads to accumulation of heparan sulfate in lysosomes throughout the body, particularly affecting the brain and causing progressive neurodegeneration [2].
NAGLU encodes alpha-N-acetylglucosaminidase, a lysosomal enzyme that catalyzes the N-acetylglucosaminide hydrolysis in heparan sulfate glycosaminoglycans. This enzyme is essential for the stepwise degradation of heparan sulfate (HS), a component of the extracellular matrix and cell surface.
NAGLU belongs to the family of glycosylhydrolases and specifically cleaves the α-N-acetylglucosaminide linkage in HS substrates. The enzyme requires an acidic pH optimum (pH 4.5-5.0) for optimal activity, consistent with the lysosomal environment [3].
Key functions include:
Deficiency leads to accumulation of HS in lysosomes, causing cellular toxicity and neurodegeneration.
The NAGLU protein is a homodimer with each subunit approximately 74 kDa. The enzyme contains a signal peptide directing it to the lysosome and a catalytic domain responsible for substrate hydrolysis [3].
Mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B, is caused by autosomal recessive mutations in NAGLU. It is one of four subtypes of Sanfilippo syndrome (MPS IIIA-D), each caused by deficiency of a different enzyme in HS degradation [2][4].
| Mutation Type | Effect | Severity |
|---|---|---|
| Null mutations | No enzyme activity | Severe, early onset |
| Missense mutations | Reduced activity | Variable severity |
| Late-onset variants | Partial activity | Attenuated phenotype |
Common pathogenic variants:
Neurodegeneration in MPS IIIB involves multiple interconnected mechanisms [5][6]:
NAGLU is expressed ubiquitously with highest levels in:
Enzyme activity is essential in all tissues, but neuronal dysfunction causes the most severe clinical manifestations. Expression is regulated by lysosomal stress and transcription factor EB (TFEB), the master regulator of lysosomal biogenesis [7].
NAGLU interacts with several proteins in its role in lysosomal heparan sulfate catabolism:
| Partner Protein | Interaction Type | Functional Significance |
|---|---|---|
| SGSH | Sequential processing | Works upstream in HS degradation |
| HGSNAT | Sequential processing | Works upstream in HS degradation |
| GNS | Sequential processing | Works downstream in HS degradation |
| GAGNS | Sequential processing | Works downstream in HS degradation |
| LAMP1 | Lysosomal targeting | Mediates lysosomal localization |
| LAMP2 | Lysosomal targeting | Mediates lysosomal localization |
| TFEB | Transcriptional regulation | Activates expression under starvation |
Several animal models have been developed to study MPS IIIB [8][9]:
Multiple therapeutic strategies are being developed for MPS IIIB [10][11]:
Expression data from the Allen Human Brain Atlas shows NAGLU expression across multiple brain regions, with higher expression in neurons compared to glial cells. Single-cell data indicates variable expression in different neuronal subtypes.
The study of NAGLU and Sanfilippo syndrome type B has evolved significantly since the disease was first described in 1963 by Dr. Sylvester Sanfilippo. The identification of NAGLU as the causative gene in 1995 enabled molecular diagnosis and carrier testing [1].
Historical milestones:
Research continues to drive therapeutic development, with multiple clinical trials currently underway for various treatment modalities.